Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Glutathione in Parkinson's Disease
NCT02324426Phase 1Completed
- Sponsor
- University of Washington
- Start
- Dec 2014
- Primary completion
- Mar 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glutathione in Parkinson's disease (PD), sponsored by University of Washington. Primary endpoint: Change in mean CNS glutathione concentration. Started Dec 2014; status: completed.
02
Drugs
glutathione
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02324426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02324426.